Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, Aug. 14, 2025 /CNW/ — USA News Group News Commentary – Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with oncology ventures securing hundreds of millions in funding so far in 2025. The Senate's recent restoration of $15 million for the Pancreatic Cancer Research Program (PCARP) was a win, yet its earlier elimination underscored the fragility of public support. Against this backdrop, investors are zeroing in on companies with standout science, solid pipelines, and clear regulatory strategies, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), Fate Therapeutics, Inc. (NASDAQ: FATE), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), and Nektar Therapeutics (NASDAQ: NKTR).
Global Market Insights estimates the global oncology market at US$345.1 billion in 2025 and forecasts it will climb to US$866.1 billion by 2034, growing at a robust 10.8% CAGR. The U.S. alone is expected to contribute $377.1 billion to that total. Vision Research Reports projects an even larger figure for the global cancer drug sector, predicting it will surpass US$900 billion in sales by 2034.
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has officially entered the most critical phase of its development journey—pursuing a potential registration-enabling trial in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) for its flagship asset, pelareorep.
In its latest Q2 2025 report, the company confirmed it has begun formal discussions with the U.S. Food and Drug Administration (FDA) aimed at finalizing a pivotal study design, with trial start-up activities expected to begin as early as Q4 2025.
For investors and potential partners, this represents a clear transition from promising clinical data to potential regulatory approval in one of medicine's most challenging cancer types.
'We have turned the corner from proof-of-concept studies and will be sprinting toward regulatory clarity for the remainder of the year,' said Jared Kelly, CEO of Oncolytics. 'As we shore up our intellectual property, get a clear registration path for pelareorep, and allow our GOBLET data to mature, we will establish our position as the only platform immunotherapy in gastrointestinal tumors.'
The strategic focus on mPDAC reflects both compelling clinical results and a significant market opportunity. Pelareorep is a systemically delivered oncolytic virus designed to convert immunologically 'cold' tumors—those typically invisible to the immune system—into 'hot' tumors that can respond to immunotherapy. In first-line pancreatic cancer studies, pelareorep-based regimens have demonstrated a notable 21.9% two-year overall survival rate, compared to a 9.2% historical benchmark for standard chemotherapy alone.
Even more compelling, when pelareorep was combined with chemotherapy and a checkpoint inhibitor, researchers recorded a 62% objective response rate—particularly significant given that checkpoint inhibitors are not currently approved for use in this indication. These results stem from pelareorep's dual mechanism: it both replicates within cancer cells and activates the body's immune response against tumors.
'This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep's immune-mediated mechanism of action,' said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. 'We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME—all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep.'
Translational data from the GOBLET and AWARE-1 studies demonstrate how pelareorep transforms the tumor microenvironment, increasing PD-L1 expression, heightening interferon signaling, and mobilizing tumor-infiltrating lymphocytes in the blood—changes that correlate with tumor size reduction. This mechanistic validation, combined with survival data from over 1,100 patients across multiple studies, has solidified the company's decision to prioritize this indication.
Oncolytics' execution-focused strategy is being led by Jared Kelly and Andrew Aromando, who both played key roles in Ambrx Biopharma's US$2 billion acquisition by Johnson & Johnson. Kelly was appointed CEO earlier this year, while Aromando recently joined as Chief Business Officer. In line with their focus on capital efficiency, the company has terminated its At-the-Market and Equity Line of Credit facilities, citing sufficient resources to advance key milestones without near-term shareholder dilution.
Regulatory advantages are already in place to accelerate development. Pelareorep holds Fast Track and Orphan Drug designations for pancreatic cancer from the FDA, meaning the agency has already recognized both the drug's potential and the serious unmet need in this patient population. These statuses streamline review processes and enhance the program's attractiveness to potential pharmaceutical partners.
The context underscores the opportunity: pancreatic cancer remains one of the deadliest common cancers, with a five-year survival rate of less than 14%. Unlike other cancers where immunotherapies have transformed treatment, mPDAC has largely resisted immunotherapeutic approaches—making pelareorep's immune-activating mechanism particularly promising for this underserved patient population.
Back in July, Oncolytics hosted a key opinion leader event featuring gastrointestinal cancer experts who reviewed survival outcomes for patients and biomarker validation. The expert panel reinforced the view that pelareorep's mechanism of activating innate and adaptive immune responses is both biologically sound and commercially relevant for first-line mPDAC treatment.
With this latest milestone, Oncolytics is entering a phase where FDA feedback will shape both clinical plans and potential commercial partnerships. If the agency accepts the company's proposed trial framework centered on an overall survival endpoint, the resulting study could provide definitive proof of pelareorep's market potential in mPDAC.
The company expects to provide an updated clinical timeline in Q3 2025, with trial start-up activities potentially beginning as early as Q4 2025. With compelling survival data, regulatory designations in place, and an experienced leadership team driving execution, Oncolytics is positioning pelareorep for a pivotal test in one of oncology's most challenging and underserved markets.
CONTINUED… Read this and more news for Oncolytics Biotech at: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/
In other recent industry developments and happenings in the market include:
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) reported strong Q2 2025 results with $60 million in total product revenue, driven primarily by its breakthrough melanoma therapy Amtagvi, which treated over 100 patients in the second quarter.
'Growth for Amtagvi and Proleukin will continue in the second half of 2025 as existing ATC growth continues and large community practices begin treating patients,' said Frederick Vogt, Ph.D., J.D., Interim President and CEO of Iovance. 'We expect our first ex-U.S. regulatory approval imminently and remain on track to provide updates on our clinical programs.'
The company's tumor-infiltrating lymphocyte (TIL) therapy—which uses a patient's own immune cells to fight cancer—generated $54.1 million in revenue and represents the first FDA-approved T-cell therapy for solid tumors, offering new hope for advanced melanoma patients who have tried other treatments without success.
With expanded clinical trials planned for lung cancer and endometrial cancer, plus international approvals expected in Canada and other markets, Iovance is positioned to bring its innovative cancer treatment to patients worldwide.
Fate Therapeutics, Inc. (NASDAQ: FATE) recently announced promising clinical progress for its off-the-shelf CAR T-cell therapy FT819, which showed lasting responses in lupus patients and received FDA clearance to begin trials for a solid tumor program targeting MICA/B proteins. While primarily focused on autoimmune diseases, the company's next-generation FT836 CAR T-cell therapy represents a significant advancement in cancer treatment as it's designed to target solid tumors without requiring harsh conditioning chemotherapy, potentially making the treatment safer and more accessible.
'Building on this momentum, we are also working closely with the FDA under our RMAT designation with the goal of commencing our registrational study for FT819 in SLE and LN in 2026,' said Bob Valamehr, Ph.D., MBA, President and CEO of Fate Therapeutics.
'Additionally, we continue to strengthen our broader pipeline programs with an extended partnership with Ono Pharmaceuticals, and advancements in bringing our next-generation, off-the-shelf CAR T cells with Sword and Shield™ technology toward the clinic.'
The company's stem cell-based platform continues to advance multiple programs, including partnerships for HER2-positive solid tumors, positioning Fate as a leader in developing ready-made cancer cell therapies.
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) remains on track to submit its application for INO-3107 in the second half of 2025, targeting Recurrent Respiratory Papillomatosis (RRP), a rare cancer-related condition caused by HPV that affects the airways. The company's DNA medicine platform represents a novel approach to treating HPV-related diseases and cancers, with INO-3107 showing significant clinical benefit by reducing the need for repeated surgeries in RRP patients from an average of 4.1 procedures annually to just 0.9 procedures.
'We believe that INO-3107 could become the preferred treatment option for Recurrent Respiratory Papillomatosis (RRP) patients and their physicians—a treatment option with the potential to change the trajectory of this disease,' said Dr. Jacqueline Shea, President and CEO of INOVIO. 'I look forward to building on the significant progress of this past quarter and providing updates as we work toward a potential approval date in mid-2026.'
Beyond RRP, Inovio's technology platform is designed to treat various HPV-related cancers and other tumors by teaching the body's immune system to recognize and fight cancer cells. With breakthrough therapy designation from the FDA and plans for a trial involving 100 patients, INO-3107 could become the first DNA-based therapy approved for treating this serious cancer-related condition.
Nektar Therapeutics (NASDAQ: NKTR) reported impressive Phase 2b data for rezpegaldesleukin in treating moderate to severe atopic dermatitis, with the company positioning this immune system regulator as a first-in-class treatment for autoimmune diseases. While primarily focused on autoimmune conditions, Nektar's pipeline includes NKTR-255, a treatment designed to boost the immune system's ability to fight cancer, which is being tested in multiple ongoing clinical trials with various partners.
'As a first-in-class, T regulatory cell biologic, rezpegaldesleukin is poised to become an important novel mechanism to treat millions of patients with autoimmune disorders,' said Howard W. Robin, President and CEO of Nektar. 'Finally, we are making significant progress on advancing preclinical studies with a new bispecific antibody, NKTR-0166, which combines the TNFR2 epitope with a validated antibody target.'
The company's technology platform creates novel treatments that could potentially address both autoimmune diseases and cancer by enhancing the immune system's cancer-fighting abilities. With additional data expected from hair loss trials in December 2025 and continued development of next-generation programs, Nektar is advancing a unique approach to immune system therapy that could benefit millions of patients with serious diseases.
Source: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/
CONTACT:
USA NEWS GROUP info@usanewsgroup.com (604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ('MIQ'). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Logo – https://mma.prnewswire.com/media/2603685/5460912/USA_News_Group_Logo.jpg
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
24 minutes ago
- The Star
Bursa Malaysia opens little changed on Friday ahead of GDP data, flat trading on Wall St
KUALA LUMPUR: Investors on Bursa Malaysia held their positions on Friday as the flattish performance on US markets overnight gave little indication on trading direction. The local bourse entered profit-taking mode yesterday as investors cashed in on a seven-day winning streak, but remained little moved at Friday's opening, ahead of Malaysia's economic report due out at noon. Traders snapped up equities over the past two weeks as risk appetite was buoyed by the continuation of US-China trade talks and investors' surging hopes for a US rate cut after a lower-than-expected inflation report. Throwing a spannar in the works, however, was the US producer's price index for July, which showed a 0.9% increase - above the 0.2% forecast by economists - which pointed to rising inflation. As at 9.10am, domestic traders remained uncertain in the absence of trading direction. The FBM KLCI was down 0.45 points to 1,580.6 while the broader market had a nearly even spread of advancers and decliners. "The local benchmark index is expected to extend its profit-taking consolidation phase, as market sentiment should remain subdued while investors await crucial domestic and U.S. data releases ahead of the weekend," said TA Securities in its daily review. Meanwhile, Rakuten Trade said in a note that foreign funds remained net sellers of local equities, which serves as a market dampener. "For today, we expect the index to hover between the 1,575-1,585 range," it added. In early trading, PETRONAS Chemicals dropped seven sne to RM3.57 while PPB shed seven sen to RM8.94 and IOI fell four sen to RM3.81. Nestle gained 26 sen to RM88.06, while PETRONAS Gas rose six sen to RM18.76 and MISC added five sen to RM7.81. Leading actives included TWL flat at 2.5 sen, Oxford Innotech up 0.5 sen to 41.5 sen and Oriental Kopi dipping one sen to 97.5 sen.
New Straits Times
an hour ago
- New Straits Times
Wall Street ends flat, but S&P hits another closing high as rate-cut bets waver
NEW YORK: Wall Street's main indexes were mixed on Thursday with S&P 500 edging up to a closing high, while the Dow Jones and Nasdaq were flat, after a hotter-than-expected producer prices report dampened expectations of potential interest-rate cuts. A Labor Department report showed producer prices increased the most in three years in July due to a surge in the costs of goods and services, suggesting a broad pickup in inflation was imminent. Traders trimmed their Fed rate-cut expectations for the rest of the year to about 56.7 basis points, according to data compiled by LSEG, compared with around 63 bps before the report. But they are still fully pricing in a quarter-percentage-point cut in September. "The implication is that the Fed is going to offer a 25-(basis point) cut in September. But it will be a hawkish cut. It's way too early still for the Fed to wish to guide the market towards an extended easing cycle," said Thierry Wizman, global FX and rates strategist at Macquarie Group. "The next important thing will be the Expenditures Price Index later this month. If there are signals that there's inflation broadly in services, the market will take that adversely." A separate report on Thursday showed the number of Americans filing new applications for jobless benefits fell last week. The Dow Jones Industrial Average closed 11.01 points, or 0.02 per cent, down to 44,911.26, the S&P 500 gained 1.96 points, or 0.03 per cent, to 6,468.54 - a new closing high - and the Nasdaq Composite lost 2.47 points, or 0.01 per cent, to 21,710.67. On Thursday, seven of the 11 S&P 500 sectors declined. Recent data reflecting labor market weakness and a moderate rise in consumer prices had strengthened expectations that the central bank will potentially lower interest rates next month. However, Thursday's report fanned concerns that US tariffs on imports could start to impact prices in the coming months and dampen a rally in US stocks that had helped the benchmark S&P 500 and tech-heavy Nasdaq log record highs over the past two sessions. "US stocks are pricy," said Sam Stovall, chief investment strategist CFRA Research. The S&P 500 index is trading at a price-to-earnings ratio of 23 based on forward estimates, or a near-40 per cent premium to its 20-year average, he said. The hotter-than-expected PPI report now has investors pulling petals from a daisy saying "They (the Fed) will cut rates, they won't cut rates," he added. St. Louis Fed President Alberto Musalem, a voting member on the Federal Open Market Committee this year, said a half-point rate cut at the Fed's September meeting is not warranted, a day after Treasury Secretary Scott Bessent said it was possible. Intel Corp rose 7.4 per cent as Bloomberg News reported the Trump administration is in talks with Intel to have the US government potentially take a stake in the chipmaker, the news organization reported on Thursday, citing people familiar with the plan. Cisco Systems declined 1.6 per cent after the network equipment manufacturer's broadly in-line forecast did little to encourage investors. Deere & Co fell 6.8 per cent after the farm-equipment maker reported a lower quarterly profit and tightened its annual profit forecast, while Tapestry plunged 15.7 per cent after the Coach handbag maker forecast annual profit below estimates. Both companies warned of tariffs impacting their businesses. In geopolitics, focus will be on President Donald Trump's upcoming meeting with Russia's President Vladimir Putin as he seeks to achieve a halt to the Ukraine conflict. Declining issues outnumbered advancers by a 2.29-to-1 ratio on the NYSE. On the Nasdaq, declining issues outnumbered advancers by a 2.14-to-1 ratio. The S&P 500 posted 15 new 52-week highs and one new low while the Nasdaq Composite recorded 78 new highs and 78 new lows. Volume on US exchanges was relatively light, with 16.3 billion shares traded, compared to an average of 18.3 billion shares over the previous 20 sessions.
The Star
an hour ago
- The Star
Trading ideas: Chin Hin, Sime Property, Catcha, Aemulus, Bursa, Malakoff, JS Solar, Cuckoo, Keyfield, I-Bhd, MNRB, Swift, JPG, N2N
KUALA LUMPUR: Here is a recap of the announcements that made headlines in Corporate Malaysia. Chin Hin Group Property Bhd is disposing of its entire equity interest in four subsidiaries involved in the commercial vehicles and bodyworks segment to N&K Resources (M) Sdn Bhd for RM74mn. Sime Darby Property Bhd is in talks with banks for a loan of up to RM3bn (US$714mn) to fund the construction of a data centre to be leased to Google, according to sources. Catcha Digital Bhd will acquire a 60% stake in One International Exhibition Sdn Bhd for RM11.4mn cash via its wholly owned unit Catcha Connect Sdn Bhd. Aemulus Holdings Bhd will acquire the camera sensor testing business of China-based Revotronix group for RMB32.46mn (RM19.1mn). Bursa Malaysia Bhd has appointed Datuk Mohamed Rafique Merican as independent non-executive director effective Aug 15, 2025. Malakoff Corp Bhd has appointed Syahrunizam Samsudin as group CEO effective Sept 1, succeeding Anwar Syahrin Abdul Ajib, who is stepping down after nearly five years as MD and group CEO. JS Solar Holding Bhd has signed an agreement with TA Securities Holdings Bhd to underwrite 35.75mn shares for its ACE Market listing targeted for 3Q2025. Cuckoo International (Mal) Bhd posted a 1.8% QoQ decline in 2QFY2025 net profit to RM27.4mn, mainly due to listing expenses of RM4.7mn and higher net impairment losses on financial instruments. Keyfield International Bhd posted a net profit of RM66.4mn in 2QFY25, down 5.2% YoY from RM70.0mn, mainly due to fewer chartered days for both own and third-party vessels. I-Bhd more than doubled its 2QFY2025 net profit to RM11.5mn (+110% YoY) on stronger contributions from leisure and hospitality, property development, and property investment. MNRB Holdings Bhd posted a record-high 1QFY2026 net profit of RM168.4mn (+82.7% YoY), driven by strong insurance/takaful revenue growth and favourable claims experience. Swift Haulage Bhd posted a 19% YoY drop in 2QFY2025 net profit to RM6.8mn, weighed down by higher expenses despite stronger revenue. Johor Plantations Group Bhd posted a 51% YoY rise in 2QFY2025 net profit to RM75.2mn on higher CPO and PK delivery volumes and stronger OCP purchases. N2N Connect Bhd posted a 41% YoY increase in 2QFY2025 net profit to RM3.2mn, boosted by lower operating expenses and higher associate contributions.
